To receive further updates on this Gilead Sciences, Inc. (NASDAQ:GILD) trade as well as an alert when it’s time to take profits, sign up for a risk-free trial of SlingShot Trader today. 

Gilead Sciences, Inc. (NASDAQ:GILD) has been struggling since its earnings announcement in late October, even though the company beat revenue estimates by $110 million, beat earnings estimates by $0.14 per share and upgraded its EPS guidance from $0.86-$0.93 to $1.02-$1.77.

To add insult to injury, the stock just got hit with another downgrade from Argus — who dropped the stock from Buy to Hold — citing concerns the company is increasing R&D spending on the new CART-T therapies the company acquired when it bought Kite Pharma at the same time its blockbuster hepatitis C and HIV products are seeing declining sales. These concerns, coupled with the general pricing pressure the market is applying to biotechnology stocks, are likely to push GILD lower.

The stock is currently sitting around support at $72 (which was support in mid-August and resistance in late June), but we expect it to move down to its next support level at $69 (which was support in early July and resistance in early May).

‘Buy to open’ the GILD December 70 Put (GILD171215P00070000) for a maximum price of $1.50.

Follow our Facebook page to receive each Trade of the Day direct to your News Feed — and join the conversation.

You can learn more about identifying price patterns and using them to project how far you think a stock is going to move in our Advanced Technical Analysis Program.

InvestorPlace advisers John Jagerson and S. Wade Hansen, both Chartered Market Technician (CMT) designees, are co-founders of LearningMarkets.com, as well as the co-editors of SlingShot Trader, a trading service designed to help you make options profits by trading the news. Get in on the next SlingShot Trader trade and get 1 free month today by clicking here.